益母草碱及其代谢物在大鼠体内的毒代动力学研究

张金莲1,刘洪瑞1,毛 煜2,郑源婷1,蔡卫民1*

主办:上海医药工业研究院
   中国药学会
   中国化学制药工业协会
ISSN 1001-8255   CN 31-1243/R   ZYGZEA
中国医药工业杂志 ›› 2012, Vol. 43 ›› Issue (6) : 451-454.
药理与临床 Pharmacology & Clinic

益母草碱及其代谢物在大鼠体内的毒代动力学研究

作者信息 +

Toxicokinetics of Leonurine and Its Metabolite in Rats

Author information +
History +

摘要

建立了测定大鼠血浆中益母草碱(1) 及其葡萄糖醛酸结合物(2) 的LC-MS/MS 方法。考察了大鼠单次和连续28 d灌胃给予低、中、高剂量1(200、600 和2 000 mg/kg) 后1 和2 在体内的暴露水平,绘制药- 时曲线并计算毒代动力学参数。单剂量试验表明,低、中、高剂量组1 的AUC 分别为(1.946±0.908)、(7.002±2.759) 和(26.408±11.491)μmol·L-1·h,1 在大鼠体内消除行为符合线性动力学模型。多剂量试验表明,低、中、高剂量组1 的AUC 分别为(2.987±1.089)、(9.083±
3.140) 和(20.178±7.484)μmol·L-1·h。长期大剂量灌胃给予1,1 和2 均未见在大鼠体内明显蓄积,且试验过程中未见大鼠有明显的毒性反应。

Abstract

A LC-MS/MS method for determination of leonurine (1) and its metabolite leonurine-O-glucuronide (2) in rat plasma was established. After single- or multiple-dose (once daily for 28 d) ig administration of 1 at low, middle and high doses, the exposure levels of 1 and 2 in rats were investigated. The concentration-time curves of 1 and 2 were drawn and the toxicokinetic parameters were calculated. The AUC of 1 for single-dose ig administration of 200, 600, 2 000 mg/kg were (1.946±0.908), (7.002±2.759) and (26.408±11.491)μmol·L-1·h, respectively. The results suggested that the elimination behavior of 1 in rats accorded with linear dynamic model. The AUC of 1 for multipledose ig administration were (2.987±1.089), (9.083±3.140) and (20.178±7.484)μmol·L-1·h, respectively. No significant accumulation was observed after successive large dose ig administration of 1 in rats. During the experiment there was no significant toxicity in rats.

关键词

益母草碱 / 益母草碱葡萄糖醛酸结合物 / LC-MS/MS / 毒代动力学

Key words

leonurine / leonurine -O- glucuronide / LC-MS/MS / toxicokinetics

引用本文

导出引用
张金莲1,刘洪瑞1,毛 煜2,郑源婷1,蔡卫民1*. 益母草碱及其代谢物在大鼠体内的毒代动力学研究. 中国医药工业杂志. 2012, 43(6): 451-454
ZHANG Jin-Lian1, LIU Hong-Rui1, MAO Yu2, ZHENG Yuan-Ting1, CAI Wei-Min1*. Toxicokinetics of Leonurine and Its Metabolite in Rats. Chinese Journal of Pharmaceuticals. 2012, 43(6): 451-454

基金

国家“重大新药创制”科技重大专项(2009ZX09301- 011)

101

Accesses

0

Citation

Detail

段落导航
相关文章

/